Molecular mechanisms modulating the phenotype of macrophages and microglia

Frontiers in Immunology

Volumn 8, Issue NOV, 2017, Pages

  Amici, Stephanie A ^a   Dong, Joycelyn ^a,b   Guerau de Arellano, Mireia ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Northwestern University   (United States)

Author keywords

Central nervous system; Inflammation; Macrophages; Metabolism; Microglia; MicroRNA; Molecular

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; INTERFERON REGULATORY FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; MICRORNA; MYC PROTEIN; NOTCH1 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR;

BONE MARROW; CELL DIFFERENTIATION; CELL ISOLATION; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; EMBRYO DEVELOPMENT; GENE; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC CELL; INFLAMMATION; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN METABOLISM; PU 1 GENE; REVIEW; WOUND HEALING;

EID: 85034068457     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.01520     Document Type: Review

References (254)

1. Herz J, Filiano AJ, Smith A, Yogev N, Kipnis J. Myeloid cells in the central nervous system. Immunity (2017) 46:943-56. doi:10.1016/j.immuni.2017.06.007
2. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science (2010) 330:841-5. doi:10.1126/science.1194637
3. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, et al. Microglia emerge from erythromyeloid precursors via Pu.1-and Irf8-dependent pathways. Nat Neurosci (2013) 16:273-80. doi:10.1038/nn.3318
4. Gomez Perdiguero E, Schulz C, Geissmann F. Development and homeostasis of 'resident' myeloid cells: the case of the microglia. Glia (2013) 61:112-20. doi:10.1002/glia.22393
5. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 122:787-95. doi:10.1172/JCI59643
6. Gow DJ, Sester DP, Hume DA. CSF-1, IGF-1, and the control of postnatal growth and development. J Leukoc Biol (2010) 88:475-81. doi:10.1189/jlb.0310158
7. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol (2009) 9:259-70. doi:10.1038/nri2528
8. Waisman A, Ginhoux F, Greter M, Bruttger J. Homeostasis of microglia in the adult brain: review of novel microglia depletion systems. Trends Immunol (2015) 36:625-36. doi:10.1016/j.it.2015.08.005
9. Benoit M, Desnues B, Mege J-L. Macrophage polarization in bacterial infections. J Immunol (2008) 181:3733-9. doi:10.4049/jimmunol.181.6.3733
10. Andersson U, Wang H, Palmblad K, Aveberger A-C, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (Hmg-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med (2000) 192:565-70. doi:10.1084/jem.192.4.565
11. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci (2005) 8:752-8. doi:10.1038/nn1472
12. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (2005) 308:1314-8. doi:10.1126/science.1110647
13. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol (2012) 13:1118-28. doi:10.1038/ni.2419
14. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity (2014) 40:274-88. doi:10.1016/j.immuni.2014.01.006
15. Wu Y, Dissing-Olesen L, MacVicar BA, Stevens B. Microglia: dynamic mediators of synapse development and plasticity. Trends Immunol (2015) 36:605-13. doi:10.1016/j.it.2015.08.008
16. Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, et al. Synaptic pruning by microglia is necessary for normal brain development. Science (2011) 333:1456-8. doi:10.1126/science.1202529
17. Davies LC, Taylor PR. Tissue-resident macrophages: then and now. Immunology (2015) 144:541-8. doi:10.1111/imm.12451
18. Jakubzick C, Gautier EL, Gibbings SL, Sojka DK, Schlitzer A, Johnson TE, et al. Minimal differentiation of classical monocytes as they survey steady-state tissues and transport antigen to lymph nodes. Immunity (2013) 39:599-610. doi:10.1016/j.immuni.2013.08.007
19. Ginhoux F, Guilliams M. Tissue-resident macrophage ontogeny and homeostasis. Immunity (2016) 44:439-49. doi:10.1016/j.immuni.2016.02.024
20. Hoeffel G, Chen J, Lavin Y, Low D, Almeida FF, See P, et al. C-Myb(+) erythro-myeloid progenitor-derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity (2015) 42:665-78. doi:10.1016/j.immuni.2015.03.011
21. Sheng J, Ruedl C, Karjalainen K. Fetal HSCs versus EMP2s. Immunity (2015) 43:1025. doi:10.1016/j.immuni.2015.11.023
22. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature (2015) 518:547-51. doi:10.1038/nature13989
23. Wong K, Noubade R, Manzanillo P, Ota N, Foreman O, Hackney JA, et al. Mice deficient in NRROS show abnormal microglial development and neurological disorders. Nat Immunol (2017) 18:633-41. doi:10.1038/ni.3743
24. Ford AL, Goodsall AL, Hickey WF, Sedgwick JD. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J Immunol (1995) 154:4309-21
25. Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A (2016) 113:E1738-46. doi:10.1073/pnas.1525528113
26. Mizutani M, Pino PA, Saederup N, Charo IF, Ransohoff RM, Cardona AE. The fractalkine receptor but not CCR2 is present on microglia from embryonic development throughout adulthood. J Immunol (2012) 188:29-36. doi:10.4049/jimmunol.1100421
27. Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci (2006) 9:917-24. doi:10.1038/nn1715
28. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol (2000) 20:4106-14. doi:10.1128/MCB.20.11.4106-4114.2000
29. O'Koren EG, Mathew R, Saban DR. Fate mapping reveals that microglia and recruited monocyte-derived macrophages are definitively distinguishable by phenotype in the retina. Sci Rep (2016) 6:20636. doi:10.1038/srep20636
30. Biber K, Neumann H, Inoue K, Boddeke HWGM. Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci (2007) 30:596-602. doi:10.1016/j.tins.2007.08.007
31. Garcia JA, Pino PA, Mizutani M, Cardona SM, Charo IF, Ransohoff RM, et al. Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation. J Immunol (2013) 191:1063-72. doi:10.4049/jimmunol.1300040
32. Freria CM, Hall JCE, Wei P, Guan Z, McTigue DM, Popovich PG. Deletion of the fractalkine receptor, CX3CR1, improves endogenous repair, axon sprouting, and synaptogenesis after spinal cord injury in mice. J Neurosci (2017) 37:3568-87. doi:10.1523/JNEUROSCI.2841-16.2017
33. Fabriek BO, Møller HJ, Vloet RPM, van Winsen LM, Hanemaaijer R, Teunissen CE, et al. Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. J Neuroimmunol (2007) 187:179-86. doi:10.1016/j.jneuroim.2007.04.016
34. Stilund M, Reuschlein A-K, Christensen T, Møller HJ, Rasmussen PV, Petersen T. Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis. PLoS One (2014) 9:e98588. doi:10.1371/journal.pone.0098588
35. Stilund M, Gjelstrup MC, Petersen T, Møller HJ, Rasmussen PV, Christensen T. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. PLoS One (2015) 10:e0119681. doi:10.1371/journal.pone.0119681
36. Bogie JF, Boelen E, Louagie E, Delputte P, Elewaut D, van Horssen J, et al. CD169 is a marker for highly pathogenic phagocytes in multiple sclerosis. Mult Scler (2017) 101:1352458517698759. doi:10.1177/1352458517698759
37. Satoh J-I, Kino Y, Asahina N, Takitani M, Miyoshi J, Ishida T, et al. TMEM119 marks a subset of microglia in the human brain. Neuropathology (2016) 36:39-49. doi:10.1111/neup.12235
38. Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis. Brain (2017) 140:1900-13. doi:10.1093/brain/awx113
39. Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci (2014) 17:131-43. doi:10.1038/nn.3599
40. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol (2007) 81:1-5. doi:10.1189/jlb.0306164
41. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep (2014) 6:13. doi:10.12703/P6-13
42. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity (2014) 41:14-20. doi:10.1016/j.immuni.2014.06.008
43. Jaguin M, Houlbert N, Fardel O, Lecureur V. Polarization profiles of human M-CSF-generated macrophages and comparison of M1-markers in classically activated macrophages from GM-CSF and M-CSF origin. Cell Immunol (2013) 281:51-61. doi:10.1016/j.cellimm.2013.01.010
44. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A (1997) 94:5243-8. doi:10.1073/pnas.94.10.5243
45. Arnold CE, Whyte CS, Gordon P, Barker RN, Rees AJ, Wilson HM. A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo. Immunology (2014) 141:96-110. doi:10.1111/imm.12173
46. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol (2008) 8:958-69. doi:10.1038/nri2448
47. Jablonski KA, Amici SA, Webb LM, de Dios Ruiz-Rosado J, Popovich PG, Partida-Sánchez S, et al. Novel markers to delineate murine M1 and M2 macrophages. PLoS One (2015) 10:e0145342. doi:10.1371/journal.pone.0145342
48. Herrmann MM, Barth S, Greve B, Schumann KM, Bartels A, Weissert R. Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Dis Model Mech (2016) 9:1211-20. doi:10.1242/dmm.025536
49. Partida-Sánchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B, et al. Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med (2001) 7:1209-16. doi:10.1038/nm1101-1209
50. Matalonga J, Glaria E, Bresque M, Escande C, Carbó JM, Kiefer K, et al. The nuclear receptor LXR limits bacterial infection of host macrophages through a mechanism that impacts cellular NAD metabolism. Cell Rep (2017) 18:1241-55. doi:10.1016/j.celrep.2017.01.007
51. Hanisch U-K, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci (2007) 10:1387-94. doi:10.1038/nn1997
52. Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol (2009) 4:389-98. doi:10.1007/s11481-009-9171-5
53. Colton CA, Wilcock DM. Assessing activation states in microglia. CNS Neurol Disord Drug Targets (2010) 9:174-91. doi:10.2174/187152710791012053
54. Varnum MM, Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) (2012) 60:251-66. doi:10.1007/s00005-012-0181-2
55. Boche D, Perry VH, Nicoll JAR. Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol (2013) 39:3-18. doi:10.1111/nan.12011
56. Mayo L, Jacob-Hirsch J, Amariglio N, Rechavi G, Moutin M-J, Lund FE, et al. Dual role of CD38 in microglial activation and activation-induced cell death. J Immunol (2008) 181:92-103. doi:10.4049/jimmunol.181.1.92
57. Durafourt BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, Guiot M-C, et al. Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia (2012) 60:717-27. doi:10.1002/glia.22298
58. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature (2014) 510:92-101. doi:10.1038/nature13479
59. Chiurchiù V, Maccarrone M. Bioactive lipids as modulators of immunity, inflammation and emotions. Curr Opin Pharmacol (2016) 29:54-62. doi:10.1016/j.coph.2016.06.005
60. Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, et al. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. Science (2017) 356:1072-6. doi:10.1126/science.aai8132
61. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia (2010) 58:1017-30. doi:10.1002/glia.20983
62. Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggström JZ, Petasis NA, et al. The novel 13S, 14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J (2013) 27:2573-83. doi:10.1096/fj.13-227728
63. Koh TJ, DiPietro LA. Inflammation and wound healing: the role of the macrophage. Expert Rev Mol Med (2011) 13:e23. doi:10.1017/S1462399411001943
64. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol (2004) 25:677-86. doi:10.1016/j.it.2004.09.015
65. Davis MJ, Tsang TM, Qiu Y, Dayrit JK, Freij JB, Huffnagle GB, et al. Macrophage M1/M2 polarization dynamically adapts to changes in cytokine microenvironments in Cryptococcus neoformans infection. MBio (2013) 4:e00264-13. doi:10.1128/mBio.00264-13
66. Brancato SK, Albina JE. Wound macrophages as key regulators of repair: origin, phenotype, and function. Am J Pathol (2011) 178:19-25. doi:10.1016/j.ajpath.2010.08.003
67. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity (2010) 32:593-604. doi:10.1016/j.immuni.2010.05.007
68. Raes G, De Baetselier P, Noël W, Beschin A, Brombacher F, Hassanzadeh Gh G. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol (2002) 71:597-602
69. Duluc D, Delneste Y, Tan F, Moles M-P, Grimaud L, Lenoir J, et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood (2007) 110:4319-30. doi:10.1182/blood-2007-02-072587
70. Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm (2015) 2015:816460. doi:10.1155/2015/816460
71. Pello OM, De Pizzol M, Mirolo M, Soucek L, Zammataro L, Amabile A, et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology. Blood (2012) 119:411-21. doi:10.1182/blood-2011-02-339911
72. Chávez-Galán L, Olleros ML, Vesin D, Garcia I. Much more than M1 and M2 macrophages, there are also CD169(+) and TCR(+) macrophages. Front Immunol (2015) 6:263. doi:10.3389/fimmu.2015.00263
73. Zizzo G, Hilliard BA, Monestier M, Cohen PL. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol (2012) 189:3508-20. doi:10.4049/jimmunol.1200662
74. Yu Y-RA, Hotten DF, Malakhau Y, Volker E, Ghio AJ, Noble PW, et al. Flow cytometric analysis of myeloid cells in human blood, bronchoalveolar lavage, and lung tissues. Am J Respir Cell Mol Biol (2016) 54:13-24. doi:10.1165/rcmb.2015-0146OC
75. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci (2009) 29:13435-44. doi:10.1523/JNEUROSCI.3257-09.2009
76. Barnett MH, Henderson APD, Prineas JW. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler (2006) 12:121-32. doi:10.1191/135248506ms1304rr
77. Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, Fatimy El R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity (2017) 47:566-81.e9. doi:10.1016/j.immuni.2017.08.008
78. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature (2017) 541:481-7. doi:10.1038/nature21029
79. Bogie JFJ, Jorissen W, Mailleux J, Nijland PG, Zelcer N, Vanmierlo T, et al. Myelin alters the inflammatory phenotype of macrophages by activating PPARs. Acta Neuropathol Commun (2013) 1:43. doi:10.1186/2051-5960-1-43
80. Raine CS. Multiple sclerosis: the resolving lesion revealed. J Neuroimmunol (2017) 304:2-6. doi:10.1016/j.jneuroim.2016.05.021
81. Miron VE, Boyd A, Zhao J-W, Yuen TJ, Ruckh JM, Shadrach JL, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci (2013) 16:1211-8. doi:10.1038/nn.3469
82. Tierney JB, Kharkrang M, La Flamme AC. Type II-activated macrophages suppress the development of experimental autoimmune encephalomyelitis. Immunol Cell Biol (2009) 87:235-40. doi:10.1038/icb.2008.99
83. Jiang H-R, Milovanovic M, Allan D, Niedbala W, Besnard A-G, Fukada SY, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-? production and inducing alternatively activated macrophages. Eur J Immunol (2012) 42:1804-14. doi:10.1002/eji.201141947
84. Terrazas C, de Dios Ruiz-Rosado J, Amici SA, Jablonski KA, Martinez-Saucedo D, Webb LM, et al. Helminth-induced Ly6C(hi) monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep (2017) 7:40814. doi:10.1038/srep40814
85. Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C. Akt signaling pathway in macrophage activation and M1/M2 polarization. J Immunol (2017) 198:1006-14. doi:10.4049/jimmunol.1601515
86. López-Peláez M, Soria-Castro I, Boscá L, Fernández M, Alemany S. Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: implications for NO synthase 2 expression. Eur J Immunol (2011) 41:1733-41. doi:10.1002/eji.201041101
87. Luyendyk JP, Schabbauer GA, Tencati M, Holscher T, Pawlinski R, Mackman N. Genetic analysis of the role of the PI3K-Akt pathway in lipopolysaccharide-induced cytokine and tissue factor gene expression in monocytes/macrophages. J Immunol (2008) 180:4218-26. doi:10.4049/jimmunol.180.6.4218
88. Díaz-Guerra MJ, Castrillo A, Martín-Sanz P, Boscá L. Negative regulation by phosphatidylinositol 3-kinase of inducible nitric oxide synthase expression in macrophages. J Immunol (1999) 162:6184-90
89. Polumuri SK, Toshchakov VY, Vogel SN. Role of phosphatidylinositol-3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc gamma receptor ligation in murine macrophages. J Immunol (2007) 179:236-46. doi:10.4049/jimmunol.179.1.236
90. Pengal RA, Ganesan LP, Wei G, Fang H, Ostrowski MC, Tridandapani S. Lipopolysaccharide-induced production of interleukin-10 is promoted by the serine/threonine kinase Akt. Mol Immunol (2006) 43:1557-64. doi:10.1016/j.molimm.2005.09.022
91. Arranz A, Doxaki C, Vergadi E, la Torre de YM, Vaporidi K, Lagoudaki ED, et al. Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci U S A (2012) 109:9517-22. doi:10.1073/pnas.1119038109
92. Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci U S A (2008) 105:8292-7. doi:10.1073/pnas.0707761105
93. Vergadi E, Vaporidi K, Theodorakis EE, Doxaki C, Lagoudaki E, Ieronymaki E, et al. Akt2 deficiency protects from acute lung injury via alternative macrophage activation and miR-146a induction in mice. J Immunol (2014) 192:394-406. doi:10.4049/jimmunol.1300959
94. Kuijl C, Savage NDL, Marsman M, Tuin AW, Janssen L, Egan DA, et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature (2007) 450:725-30. doi:10.1038/nature06345
95. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity (2009) 31:220-31. doi:10.1016/j.immuni.2009.06.024
96. Jablonski KA, Gaudet AD, Amici SA, Popovich PG, Guerau-de-Arellano M. Control of the inflammatory macrophage transcriptional signature by miR-155. PLoS One (2016) 11:e0159724. doi:10.1371/journal.pone.0159724
97. Cai X, Yin Y, Li N, Zhu D, Zhang J, Zhang C-Y, et al. Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155. J Mol Cell Biol (2012) 4:341-3. doi:10.1093/jmcb/mjs044
98. Ruffell D, Mourkioti F, Gambardella A, Kirstetter P, Lopez RG, Rosenthal N, et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc Natl Acad Sci U S A (2009) 106:17475-80. doi:10.1073/pnas.0908641106
99. Nandan D, Camargo de Oliveira C, Moeenrezakhanlou A, Lopez M, Silverman JM, Subek J, et al. Myeloid cell IL-10 production in response to Leishmania involves inactivation of glycogen synthase kinase-3β downstream of phosphatidylinositol-3 kinase. J Immunol (2012) 188:367-78. doi:10.4049/jimmunol.1100076
100. Gao M, Wang X, Zhang X, Ha T, Ma H, Liu L, et al. Attenuation of cardiac dysfunction in polymicrobial sepsis by microRNA-146a is mediated via targeting of IRAK1 and TRAF6 expression. J Immunol (2015) 195:672-82. doi:10.4049/jimmunol.1403155
101. Li X, Ji Z, Li S, Sun Y-N, Liu J, Liu Y, et al. miR-146a-5p antagonized AGEs-and P.g-LPS-induced ABCA1 and ABCG1 dysregulation in macrophages via IRAK-1 downregulation. Inflammation (2015) 38:1761-8. doi:10.1007/s10753-015-0153-x
102. He X, Tang R, Sun Y, Wang Y-G, Zhen K-Y, Zhang D-M, et al. MicroR-146 blocks the activation of M1 macrophage by targeting signal transducer and activator of transcription 1 in hepatic schistosomiasis. EBioMedicine (2016) 13:339-47. doi:10.1016/j.ebiom.2016.10.024
103. Sharma N, Verma R, Kumawat KL, Basu A, Singh SK. miR-146a suppresses cellular immune response during Japanese encephalitis virus JaOArS982 strain infection in human microglial cells. J Neuroinflammation (2015) 12:30. doi:10.1186/s12974-015-0249-0
104. Tsiperson V, Gruber RC, Goldberg MF, Jordan A, Weinger JG, Macian F, et al. Suppression of inflammatory responses during myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis is regulated by AKT3 signaling. J Immunol (2013) 190:1528-39. doi:10.4049/jimmunol.1201387
105. Fang C, Yu J, Luo Y, Chen S, Wang W, Zhao C, et al. Tsc1 is a critical regulator of macrophage survival and function. Cell Physiol Biochem (2015) 36:1406-18. doi:10.1159/000430306
106. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity (2008) 29:565-77. doi:10.1016/j.immuni.2008.08.012
107. Brown J, Wang H, Suttles J, Graves DT, Martin M. Mammalian target of rapamycin complex 2 (mTORC2) negatively regulates toll-like receptor 4-mediated inflammatory response via FoxO1. J Biol Chem (2011) 286:44295-305. doi:10.1074/jbc.M111.258053
108. Festuccia WT, Pouliot P, Bakan I, Sabatini DM, Laplante M. Myeloid-specific Rictor deletion induces M1 macrophage polarization and potentiates in vivo pro-inflammatory response to lipopolysaccharide. PLoS One (2014) 9:e95432. doi:10.1371/journal.pone.0095432
109. Byles V, Covarrubias AJ, Ben-Sahra I, Lamming DW, Sabatini DM, Manning BD, et al. The TSC-mTOR pathway regulates macrophage polarization. Nat Commun (2013) 4:2834. doi:10.1038/ncomms3834
110. Covarrubias AJ, Aksoylar HI, Yu J, Snyder NW, Worth AJ, Iyer SS, et al. Akt-mTORC1 signaling regulates Acly to integrate metabolic input to control of macrophage activation. Elife (2016) 5:R106. doi:10.7554/eLife.11612
111. Pan H, O'Brien TF, Zhang P, Zhong X-P. The role of tuberous sclerosis complex 1 in regulating innate immunity. J Immunol (2012) 188:3658-66. doi:10.4049/jimmunol.1102187
112. Mercalli A, Calavita I, Dugnani E, Citro A, Cantarelli E, Nano R, et al. Rapamycin unbalances the polarization of human macrophages to M1. Immunology (2013) 140:179-90. doi:10.1111/imm.12126
113. Radtke F, MacDonald HR, Tacchini-Cottier F. Regulation of innate and adaptive immunity by Notch. Nat Rev Immunol (2013) 13:427-37. doi:10.1038/nri3445
114. Nakano T, Fukuda D, Koga J-I, Aikawa M. Delta-like ligand 4-notch signaling in macrophage activation. Arterioscler Thromb Vasc Biol (2016) 36:2038-47. doi:10.1161/ATVBAHA.116.306926
115. Fung E, Tang S-MT, Canner JP, Morishige K, Arboleda-Velasquez JF, Cardoso AA, et al. Delta-like 4 induces notch signaling in macrophages: implications for inflammation. Circulation (2007) 115:2948-56. doi:10.1161/CIRCULATIONAHA.106.675462
116. Monsalve E, Ruiz-García A, Baladrón V, Ruiz-Hidalgo MJ, Sánchez-Solana B, Rivero S, et al. Notch1 upregulates LPS-induced macrophage activation by increasing NF-kappaB activity. Eur J Immunol (2009) 39:2556-70. doi:10.1002/eji.200838722
117. Xu H, Zhu J, Smith S, Foldi J, Zhao B, Chung AY, et al. Notch-RBP-J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat Immunol (2012) 13:642-50. doi:10.1038/ni.2304
118. Palaga T, Buranaruk C, Rengpipat S, Fauq AH, Golde TE, Kaufmann SHE, et al. Notch signaling is activated by TLR stimulation and regulates macrophage functions. Eur J Immunol (2008) 38:174-83. doi:10.1002/eji.200636999
119. Monsalve E, Pérez MA, Rubio A, Ruiz-Hidalgo MJ, Baladrón V, García-Ramírez JJ, et al. Notch-1 up-regulation and signaling following macrophage activation modulates gene expression patterns known to affect antigen-presenting capacity and cytotoxic activity. J Immunol (2006) 176:5362-73. doi:10.4049/jimmunol.176.9.5362
120. Boonyatecha N, Sangphech N, Wongchana W, Kueanjinda P, Palaga T. Involvement of Notch signaling pathway in regulating IL-12 expression via c-Rel in activated macrophages. Mol Immunol (2012) 51:255-62. doi:10.1016/j.molimm.2012.03.017
121. Wang Y, Huang J-W, Calses P, Kemp CJ, Taniguchi T. miR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition. Cancer Res (2012) 72:4037-46. doi:10.1158/0008-5472.CAN-12-0103
122. Outtz HH, Wu JK, Wang X, Kitajewski J. Notch1 deficiency results in decreased inflammation during wound healing and regulates vascular endothelial growth factor receptor-1 and inflammatory cytokine expression in macrophages. J Immunol (2010) 185:4363-73. doi:10.4049/jimmunol.1000720
123. Singla RD, Wang J, Singla DK. Regulation of Notch 1 signaling in THP-1 cells enhances M2 macrophage differentiation. Am J Physiol Heart Circ Physiol (2014) 307:H1634-42. doi:10.1152/ajpheart.00896.2013
124. Xu J, Chi F, Guo T, Punj V, Lee WNP, French SW, et al. NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. J Clin Invest (2015) 125:1579-90. doi:10.1172/JCI76468
125. Cao Q, Li P, Lu J, Dheen ST, Kaur C, Ling E-A. Nuclear factor-?B/p65 responds to changes in the Notch signaling pathway in murine BV-2 cells and in amoeboid microglia in postnatal rats treated with the ?-secretase complex blocker DAPT. J Neurosci Res (2010) 88:2701-14. doi:10.1002/jnr.22429
126. Wei Z, Chigurupati S, Arumugam TV, Jo D-G, Li H, Chan SL. Notch activation enhances the microglia-mediated inflammatory response associated with focal cerebral ischemia. Stroke (2011) 42:2589-94. doi:10.1161/STROKEAHA.111.614834
127. Yao L, Kan EM, Kaur C, Dheen ST, Hao A, Lu J, et al. Notch-1 signaling regulates microglia activation via NF-?B pathway after hypoxic exposure in vivo and in vitro. PLoS One (2013) 8:e78439. doi:10.1371/journal.pone.0078439
128. Wongchana W, Lawlor RG, Osborne BA, Palaga T. Impact of Notch1 deletion in macrophages on proinflammatory cytokine production and the outcome of experimental autoimmune encephalomyelitis. J Immunol (2015) 195:5337-46. doi:10.4049/jimmunol.1401770
129. Wang CYY, Wei Q, Han I, Sato S, Ghanbari-Azarnier R, Whetstone H, et al. Hedgehog and Notch signaling regulate self-renewal of undifferentiated pleomorphic sarcomas. Cancer Res (2012) 72:1013-22. doi:10.1158/0008-5472.CAN-11-2531
130. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 58:726-41. doi:10.1124/pr.58.4.5
131. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 49:497-505. doi:10.1007/s000110050622
132. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C, et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature (1999) 400:378-82. doi:10.1038/22572
133. Coste A, Dubourdeau M, Linas MD, Cassaing S, Lepert J-C, Balard P, et al. PPARgamma promotes mannose receptor gene expression in murine macrophages and contributes to the induction of this receptor by IL-13. Immunity (2003) 19:329-39. doi:10.1016/S1074-7613(03)00229-2
134. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol (2007) 28:551-8. doi:10.1016/j.it.2007.09.003
135. Lovett-Racke AE, Hussain RZ, Northrop S, Choy J, Rocchini A, Matthes L, et al. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol (2004) 172:5790-8. doi:10.4049/jimmunol.172.9.5790
136. Dunn SE, Ousman SS, Sobel RA, Zuniga L, Baranzini SE, Youssef S, et al. Peroxisome proliferator-activated receptor (PPAR)alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med (2007) 204:321-30. doi:10.1084/jem.20061839
137. Manoharan I, Suryawanshi A, Hong Y, Ranganathan P, Shanmugam A, Ahmad S, et al. Homeostatic PPARa signaling limits inflammatory responses to commensal microbiota in the intestine. J Immunol (2016) 196:4739-49. doi:10.4049/jimmunol.1501489
138. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab (2007) 6:137-43. doi:10.1016/j.cmet.2007.06.010
139. Dasu MR, Park S, Devaraj S, Jialal I. Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology (2009) 150:3457-64. doi:10.1210/en.2008-1757
140. Yang W-S, Jeng C-Y, Wu T-J, Tanaka S, Funahashi T, Matsuzawa Y, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care (2002) 25:376-80. doi:10.2337/diacare.25.2.376
141. Feng X, Weng D, Zhou F, Owen YD, Qin H, Zhao J, et al. Activation of PPAR? by a natural flavonoid modulator, apigenin ameliorates obesity-related inflammation via regulation of macrophage polarization. EBioMedicine (2016) 9:61-76. doi:10.1016/j.ebiom.2016.06.017
142. Han Q, Yuan Q, Meng X, Huo J, Bao Y, Xie G. 6-Shogaol attenuates LPS-induced inflammation in BV2 microglia cells by activating PPAR-?. Oncotarget (2017) 8:42001-6. doi:10.18632/oncotarget.16719
143. Kielian T, Drew PD. Effects of peroxisome proliferator-activated receptor-gamma agonists on central nervous system inflammation. J Neurosci Res (2003) 71:315-25. doi:10.1002/jnr.10501
144. Kang K, Reilly SM, Karabacak V, Gangl MR, Fitzgerald K, Hatano B, et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab (2008) 7:485-95. doi:10.1016/j.cmet.2008.04.002
145. Odegaard JI, Ricardo-Gonzalez RR, Red Eagle A, Vats D, Morel CR, Goforth MH, et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab (2008) 7:496-507. doi:10.1016/j.cmet.2008.04.003
146. Polak PE, Kalinin S, Russo Dello C, Gavrilyuk V, Sharp A, Peters JM, et al. Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 168:65-75. doi:10.1016/j.jneuroim.2005.07.006
147. Bassaganya-Riera J, DiGuardo M, Climent M, Vives C, Carbo A, Jouni ZE, et al. Activation of PPAR? and d by dietary punicic acid ameliorates intestinal inflammation in mice. Br J Nutr (2011) 106:878-86. doi:10.1017/S0007114511001188
148. Kanakasabai S, Chearwae W, Walline CC, Iams W, Adams SM, Bright JJ. Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis. Immunology (2010) 130:572-88. doi:10.1111/j.1365-2567.2010.03261.x
149. Adhikary T, Wortmann A, Schumann T, Finkernagel F, Lieber S, Roth K, et al. The transcriptional PPARβ/d network in human macrophages defines a unique agonist-induced activation state. Nucleic Acids Res (2015) 43:5033-51. doi:10.1093/nar/gkv331
150. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med (2013) 3:a014217. doi:10.1101/cshperspect.a014217
151. Pello OM, Chèvre R, Laoui D, De Juan A, Lolo F, Andrés-Manzano MJ, et al. In vivo inhibition of c-MYC in myeloid cells impairs tumor-associated macrophage maturation and pro-tumoral activities. PLoS One (2012) 7:e45399. doi:10.1371/journal.pone.0045399
152. Liu L, Lu Y, Martinez J, Bi Y, Lian G, Wang T, et al. Proinflammatory signal suppresses proliferation and shifts macrophage metabolism from Myc-dependent to HIF1a-dependent. Proc Natl Acad Sci U S A (2016) 113:1564-9. doi:10.1073/pnas.1518000113
153. Huang SC-C, Smith AM, Everts B, Colonna M, Pearce EL, Schilling JD, et al. Metabolic reprogramming mediated by the mTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity (2016) 45:817-30. doi:10.1016/j.immuni.2016.09.016
154. Takaoka A, Tamura T, Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci (2008) 99:467-78. doi:10.1111/j.1349-7006.2007.00720.x
155. Günthner R, Anders H-J. Interferon-regulatory factors determine macrophage phenotype polarization. Mediators Inflamm (2013) 2013:731023-8. doi:10.1155/2013/731023
156. Saliba DG, Heger A, Eames HL, Oikonomopoulos S, Teixeira A, Blazek K, et al. IRF5:RelA interaction targets inflammatory genes in macrophages. Cell Rep (2014) 8:1308-17. doi:10.1016/j.celrep.2014.07.034
157. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol (2011) 12:231-8. doi:10.1038/ni.1990
158. Takaoka A, Yanai H, Kondo S, Duncan G, Negishi H, Mizutani T, et al. Integral role of IRF-5 in the gene induction programme activated by toll-like receptors. Nature (2005) 434:243-9. doi:10.1038/nature03308
159. Kristjansdottir G, Sandling JK, Bonetti A, Roos IM, Milani L, Wang C, et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet (2008) 45:362-9. doi:10.1136/jmg.2007.055012
160. Ding L, Gu H, Gao X, Xiong S, Zheng B. Aurora kinase a regulates m1 macrophage polarization and plays a role in experimental autoimmune encephalomyelitis. Inflammation (2015) 38:800-11. doi:10.1007/s10753-014-9990-2
161. Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M, et al. Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in toll-like receptor-dependent gene induction program. Proc Natl Acad Sci U S A (2006) 103:15136-41. doi:10.1073/pnas.0607181103
162. Roy S, Guler R, Parihar SP, Schmeier S, Kaczkowski B, Nishimura H, et al. Batf2/Irf1 induces inflammatory responses in classically activated macrophages, lipopolysaccharides, and mycobacterial infection. J Immunol (2015) 194:6035-44. doi:10.4049/jimmunol.1402521
163. Masumi A, Tamaoki S, Wang IM, Ozato K, Komuro K. IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages. FEBS Lett (2002) 531:348-53. doi:10.1016/S0014-5793(02)03556-1
164. International Multiple Sclerosis Genetics Consortium (IMSGC)Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 45:1353-60. doi:10.1038/ng.2770
165. Disanto G, Sandve GK, Berlanga-Taylor AJ, Morahan JM, Dobson R, Giovannoni G, et al. Genomic regions associated with multiple sclerosis are active in B cells. PLoS One (2012) 7:e32281. doi:10.1371/journal.pone.0032281
166. Yoshida Y, Yoshimi R, Yoshii H, Kim D, Dey A, Xiong H, et al. The transcription factor IRF8 activates integrin-mediated TGF-β signaling and promotes neuroinflammation. Immunity (2014) 40:187-98. doi:10.1016/j.immuni.2013.11.022
167. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol (2010) 11:936-44. doi:10.1038/ni.1920
168. Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K, et al. Negative regulation of toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A (2005) 102:15989-94. doi:10.1073/pnas.0508327102
169. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 116:281-97. doi:10.1016/S0092-8674(04)00045-5
170. Hausser J, Zavolan M. Identification and consequences of miRNA-target interactions-beyond repression of gene expression. Nat Rev Genet (2014) 15:599-612. doi:10.1038/nrg3765
171. Murugaiyan G, Beynon V, Mittal A, Joller N, Weiner HL. Silencing microRNA-155 ameliorates experimental autoimmune encephalomyelitis. J Immunol (2011) 187:2213-21. doi:10.4049/jimmunol.1003952
172. Paraboschi EM, Soldà G, Gemmati D, Orioli E, Zeri G, Benedetti MD, et al. Genetic association and altered gene expression of mir-155 in multiple sclerosis patients. Int J Mol Sci (2011) 12:8695-712. doi:10.3390/ijms12128695
173. Moore CS, Rao VTS, Durafourt BA, Bedell BJ, Ludwin SK, Bar-Or A, et al. miR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization. Ann Neurol (2013) 74:709-20. doi:10.1002/ana.23967
174. Gaudet AD, Mandrekar-Colucci S, Hall JCE, Sweet DR, Schmitt PJ, Xu X, et al. miR-155 deletion in mice overcomes neuron-intrinsic and neuron-extrinsic barriers to spinal cord repair. J Neurosci (2016) 36:8516-32. doi:10.1523/JNEUROSCI.0735-16.2016
175. Tili E, Michaille J-J, Cimino A, Costinean S, Dumitru CD, Adair B, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 179:5082-9. doi:10.4049/jimmunol.179.8.5082
176. Cardoso AL, Guedes JR, Pereira de Almeida L, Pedroso de Lima MC. miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production. Immunology (2012) 135:73-88. doi:10.1111/j.1365-2567.2011.03514.x
177. Tarassishin L, Loudig O, Bauman A, Shafit-Zagardo B, Suh H-S, Lee SC. Interferon regulatory factor 3 inhibits astrocyte inflammatory gene expression through suppression of the proinflammatory miR-155 and miR-155*. Glia (2011) 59:1911-22. doi:10.1002/glia.21233
178. Herai RR, Stefanacci L, Hrvoj-Mihic B, Chailangkarn T, Hanson K, Semendeferi K, et al. Micro RNA detection in long-term fixed tissue of cortical glutamatergic pyramidal neurons after targeted laser-capture neuroanatomical microdissection. J Neurosci Methods (2014) 235:76-82. doi:10.1016/j.jneumeth.2014.06.028
179. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 104:1604-9. doi:10.1073/pnas.0610731104
180. Ceppi M, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A (2009) 106:2735-40. doi:10.1073/pnas.0811073106
181. Cobos Jiménez V, Bradley EJ, Willemsen AM, van Kampen AHC, Baas F, Kootstra NA. Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages. Physiol Genomics (2013) 46:91-103. doi:10.1152/physiolgenomics.00140.2013
182. Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem (2012) 287:21816-25. doi:10.1074/jbc.M111.327031
183. Woodbury ME, Freilich RW, Cheng CJ, Asai H, Ikezu S, Boucher JD, et al. miR-155 is essential for inflammation-induced hippocampal neurogenic dysfunction. J Neurosci (2015) 35:9764-81. doi:10.1523/JNEUROSCI.4790-14.2015
184. Freilich RW, Woodbury ME, Ikezu T. Integrated expression profiles of mRNA and miRNA in polarized primary murine microglia. PLoS One (2013) 8:e79416. doi:10.1371/journal.pone.0079416
185. Zhang Y, Zhang M, Zhong M, Suo Q, Lv K. Expression profiles of miRNAs in polarized macrophages. Int J Mol Med (2013) 31:797-802. doi:10.3892/ijmm.2013.1260
186. Alexander M, Hu R, Runtsch MC, Kagele DA, Mosbruger TL, Tolmachova T, et al. Exosome-delivered microRNAs modulate the inflammatory response to endotoxin. Nat Commun (2015) 6:7321. doi:10.1038/ncomms8321
187. Caballero-Garrido E, Pena-Philippides JC, Lordkipanidze T, Bragin D, Yang Y, Erhardt EB, et al. In vivo inhibition of miR-155 promotes recovery after experimental mouse stroke. J Neurosci (2015) 35:12446-64. doi:10.1523/JNEUROSCI.1641-15.2015
188. O'Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A (2009) 106:7113-8. doi:10.1073/pnas.0902636106
189. Zhou H, Xiao J, Wu N, Liu C, Xu J, Liu F, et al. MicroRNA-223 regulates the differentiation and function of intestinal dendritic cells and macrophages by targeting C/EBPβ. Cell Rep (2015) 13:1149-60. doi:10.1016/j.celrep.2015.09.073
190. Cao S, Liu J, Song L, Ma X. The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. J Immunol (2005) 174:3484-92. doi:10.4049/jimmunol.174.6.3484
191. Cao S, Liu J, Chesi M, Bergsagel PL, Ho I-C, Donnelly RP, et al. Differential regulation of IL-12 and IL-10 gene expression in macrophages by the basic leucine zipper transcription factor c-Maf fibrosarcoma. J Immunol (2002) 169:5715-25. doi:10.4049/jimmunol.169.10.5715
192. Schulte LN, Westermann AJ, Vogel J. Differential activation and functional specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids Res (2013) 41:542-53. doi:10.1093/nar/gks1030
193. Natsuka S, Akira S, Nishio Y, Hashimoto S, Sugita T, Isshiki H, et al. Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. Blood (1992) 79:460-6
194. Yan C, Zhu M, Staiger J, Johnson PF, Gao H. C5a-regulated CCAAT/enhancer-binding proteins β and d are essential in Fc? receptor-mediated inflammatory cytokine and chemokine production in macrophages. J Biol Chem (2012) 287:3217-30. doi:10.1074/jbc.M111.280834
195. Screpanti I, Romani L, Musiani P, Modesti A, Fattori E, Lazzaro D, et al. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J (1995) 14:1932-41
196. Gorgoni B, Maritano D, Marthyn P, Righi M, Poli V. C/EBP beta gene inactivation causes both impaired and enhanced gene expression and inverse regulation of IL-12 p40 and p35 mRNAs in macrophages. J Immunol (2002) 168:4055-62. doi:10.4049/jimmunol.168.8.4055
197. Davydov IV, Krammer PH, Li-Weber M. Nuclear factor-IL6 activates the human IL-4 promoter in T cells. J Immunol (1995) 155:5273-9
198. van Dijk TB, Baltus B, Raaijmakers JA, Lammers JW, Koenderman L, de Groot RP. A composite C/EBP binding site is essential for the activity of the promoter of the IL-3/IL-5/granulocyte-macrophage colony-stimulating factor receptor beta c gene. J Immunol (1999) 163:2674-80
199. Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL. MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-a-PU.1 pathway. Nat Med (2011) 17:64-70. doi:10.1038/nm.2266
200. Hamzei Taj S, Kho W, Aswendt M, Collmann FM, Green C, Adamczak J, et al. Dynamic modulation of microglia/macrophage polarization by miR-124 after focal cerebral ischemia. J Neuroimmune Pharmacol (2016) 11:733-48. doi:10.1007/s11481-016-9700-y
201. Banerjee S, Xie N, Cui H, Tan Z, Yang S, Icyuz M, et al. MicroRNA let-7c regulates macrophage polarization. J Immunol (2013) 190:6542-9. doi:10.4049/jimmunol.1202496
202. Chen X-M, Splinter PL, O'Hara SP, LaRusso NF. A cellular micro-RNA, let-7i, regulates toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection. J Biol Chem (2007) 282:28929-38. doi:10.1074/jbc.M702633200
203. Sharma BS, Abo-Ismail MK, Schenkel FS, You Q, Verschoor CP, Pant SD, et al. Association of TLR4 polymorphisms with Mycobacterium avium subspecies paratuberculosis infection status in Canadian Holsteins. Anim Genet (2015) 46:560-5. doi:10.1111/age.12333
204. Parisi C, Napoli G, Amadio S, Spalloni A, Apolloni S, Longone P, et al. MicroRNA-125b regulates microglia activation and motor neuron death in ALS. Cell Death Differ (2016) 23:531-41. doi:10.1038/cdd.2015.153
205. Kumar M, Sahu SK, Kumar R, Subuddhi A, Maji RK, Jana K, et al. MicroRNA let-7 modulates the immune response to Mycobacterium tuberculosis infection via control of A20, an inhibitor of the NF-?B pathway. Cell Host Microbe (2015) 17:345-56. doi:10.1016/j.chom.2015.01.007
206. Lehmann SM, Krüger C, Park B, Derkow K, Rosenberger K, Baumgart J, et al. An unconventional role for miRNA: let-7 activates toll-like receptor 7 and causes neurodegeneration. Nat Neurosci (2012) 15:827-35. doi:10.1038/nn.3113
207. Wang Z, Xu L, Hu Y, Huang Y, Zhang Y, Zheng X, et al. miRNA let-7b modulates macrophage polarization and enhances tumor-associated macrophages to promote angiogenesis and mobility in prostate cancer. Sci Rep (2016) 6:25602. doi:10.1038/srep25602
208. Corraliza IM, Soler G, Eichmann K, Modolell M. Arginase induction by suppressors of nitric oxide synthesis (IL-4, IL-10 and PGE2) in murine bone-marrow-derived macrophages. Biochem Biophys Res Commun (1995) 206:667-73. doi:10.1006/bbrc.1995.1094
209. Munder M, Eichmann K, Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol (1998) 160:5347-54
210. Van den Bossche J, O'Neill LA, Menon D. Macrophage immunometabolism: where are we (going)? Trends Immunol (2017) 38:395-406. doi:10.1016/j.it.2017.03.001
211. Newsholme P, Gordon S, Newsholme EA. Rates of utilization and fates of glucose, glutamine, pyruvate, fatty acids and ketone bodies by mouse macrophages. Biochem J (1987) 242:631-6. doi:10.1042/bj2420631
212. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol (1927) 8:519-30. doi:10.1085/jgp.8.6.519
213. Van den Bossche J, Baardman J, Otto NA, van der Velden S, Neele AE, van den Berg SM, et al. Mitochondrial dysfunction prevents repolarization of inflammatory macrophages. Cell Rep (2016) 17:684-96. doi:10.1016/j.celrep.2016.09.008
214. Haschemi A, Kosma P, Gille L, Evans CR, Burant CF, Starkl P, et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab (2012) 15:813-26. doi:10.1016/j.cmet.2012.04.023
215. Van den Bossche J, Baardman J, de Winther MPJ. Metabolic characterization of polarized M1 and M2 bone marrow-derived macrophages using real-time extracellular flux analysis. J Vis Exp (2015) 105:e53424. doi:10.3791/53424
216. Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab (2006) 4:13-24. doi:10.1016/j.cmet.2006.05.011
217. Mills EL, Kelly B, Logan A, Costa ASH, Varma M, Bryant CE, et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell (2016) 167:457-70.e13. doi:10.1016/j.cell.2016.08.064
218. O'Neill LAJ. A metabolic roadblock in inflammatory macrophages. Cell Rep (2016) 17:625-6. doi:10.1016/j.celrep.2016.09.085
219. Cordes T, Wallace M, Michelucci A, Divakaruni AS, Sapcariu SC, Sousa C, et al. Immunoresponsive gene 1 and itaconate inhibit succinate dehydrogenase to modulate intracellular succinate levels. J Biol Chem (2016) 291:14274-84. doi:10.1074/jbc.M115.685792
220. Dai X-M, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood (2002) 99:111-20. doi:10.1182/blood.V99.1.111
221. Graham DK, Dawson TL, Mullaney DL, Snodgrass HR, Earp HS. Cloning and mRNA expression analysis of a novel human protooncogene, c-mer. Cell Growth Differ (1994) 5:647-57
222. Graham DK, Bowman GW, Dawson TL, Stanford WL, Earp HS, Snodgrass HR. Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. Oncogene (1995) 10:2349-59
223. Iwama A, Okano K, Sudo T, Matsuda Y, Suda T. Molecular cloning of a novel receptor tyrosine kinase gene, STK, derived from enriched hematopoietic stem cells. Blood (1994) 83:3160-9
224. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene (1993) 8:1195-202
225. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell YW, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature (1995) 373:623-6. doi:10.1038/373623a0
226. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, Hanafusa H, et al. Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. J Biol Chem (1996) 271:30022-7. doi:10.1074/jbc.271.47.30022
227. Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ, et al. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science (1994) 266:117-9. doi:10.1126/science.7939629
228. Wang MH, Yoshimura T, Skeel A, Leonard EJ. Proteolytic conversion of single chain precursor macrophage-stimulating protein to a biologically active heterodimer by contact enzymes of the coagulation cascade. J Biol Chem (1994) 269:3436-40
229. Wang MH, Cox GW, Yoshimura T, Sheffler LA, Skeel A, Leonard EJ. Macrophage-stimulating protein inhibits induction of nitric oxide production by endotoxin-or cytokine-stimulated mouse macrophages. J Biol Chem (1994) 269:14027-31
230. Liu QP, Fruit K, Ward J, Correll PH. Negative regulation of macrophage activation in response to IFN-gamma and lipopolysaccharide by the STK/RON receptor tyrosine kinase. J Immunol (1999) 163:6606-13
231. Zhou Y-Q, Chen Y-Q, Fisher JH, Wang M-H. Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages. J Biol Chem (2002) 277:38104-10. doi:10.1074/jbc.M206167200
232. Camenisch TD, Koller BH, Earp HS, Matsushima GK. A novel receptor tyrosine kinase, Mer, inhibits TNF-alpha production and lipopolysaccharide-induced endotoxic shock. J Immunol (1999) 162:3498-503
233. Morrison AC, Wilson CB, Ray M, Correll PH. Macrophage-stimulating protein, the ligand for the stem cell-derived tyrosine kinase/RON receptor tyrosine kinase, inhibits IL-12 production by primary peritoneal macrophages stimulated with IFN-gamma and lipopolysaccharide. J Immunol (2004) 172:1825-32. doi:10.4049/jimmunol.172.3.1825
234. Lu Q, Lemke G. Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science (2001) 293:306-11. doi:10.1126/science.1061663
235. Fujimori T, Grabiec AM, Kaur M, Bell TJ, Fujino N, Cook PC, et al. The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung. Mucosal Immunol (2015) 8:1021-30. doi:10.1038/mi.2014.129
236. Seno H, Miyoshi H, Brown SL, Geske MJ, Colonna M, Stappenbeck TS. Efficient colonic mucosal wound repair requires Trem2 signaling. Proc Natl Acad Sci U S A (2009) 106:256-61. doi:10.1073/pnas.0803343106
237. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo J-L, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med (2007) 204:3037-47. doi:10.1084/jem.20070885
238. Kato M, Li J, Chuang JL, Chuang DT. Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure (2007) 15:992-1004. doi:10.1016/j.str.2007.07.001
239. Gerriets VA, Kishton RJ, Nichols AG, Macintyre AN, Inoue M, Ilkayeva O, et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation. J Clin Invest (2015) 125:194-207. doi:10.1172/JCI76012
240. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med (2012) 367:1098-107. doi:10.1056/NEJMoa1114287
241. Huang H, Taraboletti A, Shriver LP. Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes. Redox Biol (2015) 5:169-75. doi:10.1016/j.redox.2015.04.011
242. Asadullah K, Schmid H, Friedrich M, Randow F, Volk HD, Sterry W, et al. Influence of monomethylfumarate on monocytic cytokine formation-explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res (1997) 289:623-30. doi:10.1007/s004030050251
243. Peng H, Guerau-de-Arellano M, Mehta VB, Yang Y, Huss DJ, Papenfuss TL, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor ?B (NF-?B) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signaling. J Biol Chem (2012) 287:28017-26. doi:10.1074/jbc.M112.383380
244. Linker RA, Lee D-H, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 134:678-92. doi:10.1093/brain/awq386
245. Wilms H, Sievers J, Rickert U, Rostami-Yazdi M, Mrowietz U, Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation (2010) 7:30. doi:10.1186/1742-2094-7-30
246. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (2012) 122:253-70. doi:10.1042/CS20110386
247. Kelly B, Tannahill GM, Murphy MP, O'Neill LAJ. Metformin inhibits the production of reactive oxygen species from NADH:Ubiquinone oxidoreductase to limit induction of interleukin-1β (IL-1β) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. J Biol Chem (2015) 290:20348-59. doi:10.1074/jbc.M115.662114
248. Nath N, Khan M, Paintlia MK, Singh I, Hoda MN, Giri S. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol (2009) 182:8005-14. doi:10.4049/jimmunol.0803563
249. Sun Y, Tian T, Gao J, Liu X, Hou H, Cao R, et al. Metformin ameliorates the development of experimental autoimmune encephalomyelitis by regulating T helper 17 and regulatory T cells in mice. J Neuroimmunol (2016) 292:58-67. doi:10.1016/j.jneuroim.2016.01.014
250. Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol (2016) 73:520-8. doi:10.1001/jamaneurol.2015.4807
251. Haghikia A, Gold R. Positive effect on multiple sclerosis with treatment of metabolic syndrome. JAMA Neurol (2016) 73:499-501. doi:10.1001/jamaneurol.2015.5050
252. Al-Majed A, Bakheit AHH, Abdel Aziz HA, Alharbi H, Al-Jenoobi FI. Pioglitazone. Profiles Drug Subst Excip Relat Methodol (2016) 41:379-438. doi:10.1016/bs.podrm.2015.11.002
253. Feinstein DL, Galea E, Gavrilyuk V, Brosnan CF, Whitacre CC, Dumitrescu-Ozimek L, et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol (2002) 51:694-702. doi:10.1002/ana.10206
254. Storer PD, Xu J, Chavis J, Drew PD. Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol (2005) 161:113-22. doi:10.1016/j.jneuroim.2004.12.015